Single cell multiomics reveals drivers of metabolic dysfunction-associated steatohepatitis

作者：Weston Elison, Lei Chang, Yang Xie, Charlene Miciano, Qian Yang, Hannah M Mummey, Ryan Lancione, Sierra Corban, Sadatsugu Sakane, Jacinta Lucero, Sainath Mamde, Hyun Sik Kim, Matthew J Kim, Rebecca Melton, Luca Tucciarone, Anita Lie, Timothy Loe, Tanmayi D. Vashist, Kelsey Dang, Ruth M. Elgamal, Daofeng Li, M. Vu, Elie N. Farah, Chad Seng, Jovina Djulamsah, Bing Yang, Justin Buchanan, Michael I. Miller, Mai Tran, Janeth Birrueta, Neil C Chi, Ting Wang, Agnieszka D’Antonio‐Chronowska, Allen Wang, Tatiana Kisseleva, David Brenner, Bing Ren, Kyle J. Gaulton · 发表于：medRxiv · 年份：2025 · DOI：10.1101/2025.05.09.25327043 · 被引用次数：3 · 研究领域：Liver Disease Diagnosis and Treatment、Diabetes and associated disorders、Pancreatic function and diabetes

Metabolic dysfunction-associated steatotic liver disease (MASLD) has limited treatments, and cell type-specific regulatory networks driving MASLD represent therapeutic avenues. We assayed five transcriptomic and epigenomic modalities in 2.4M cells from 86 livers across MASLD stages. Integrating modalities increased annotation of the genome in liver cell types several-fold over previous catalogs. We identified cell type regulatory networks of MASLD progression, including distinct hepatocyte networks driving MASL and mild and severe fibrosis MASH. Our single cell atlas annotated 88% of MASH-associated loci, including a third affecting hepatocyte regulation which we linked to distal target genes. Finally, we characterized hepatocyte heterogeneity, including MASH-enriched populations with altered repression, localization, and signaling. Overall, our results provide high-resolution maps of liver cell types and revealed novel targets for anti-MASH therapy.